logo.jpg
Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference
May 11, 2022 08:30 ET | Stella Diagnostics, Inc
SALT LAKE CITY, May 11, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and...
logo.jpg
Stella Diagnostics Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting
April 06, 2022 08:30 ET | Stella Diagnostics, Inc
SALT LAKE CITY, April 06, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and...
Mesuron Inc. Announces Know-How License Agreement and Stock Purchase Agreement With Mayo Clinic
January 04, 2022 08:00 ET | Mesuron Inc.
LATHAM, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Mesuron announced today that it has entered into a know-how collaboration agreement and stock purchase agreement with Mayo Clinic to further refine...
LOGO.jpg
Vivos Inc Obtains Feedback from the FDA on Clinical Testing of RadioGel™
December 02, 2021 09:30 ET | Vivos Inc.
Richland WA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), on November 30 Vivos Inc met with the Food and Drug Administration to obtain suggestions on improving the current draft of...
0c16d4f934b396fffd79.png
TripleBlind Lands $24 Million in Series A Funding Led by General Catalyst and Mayo Clinic, in an Oversubscribed Round
October 18, 2021 13:00 ET | TripleBlind
Enables Enterprises to Unlock and Commercialize enormous amount of Unused Data*Mayo Clinic Joins Round as Strategic Investor, Expands Equity PositionAccenture and Mayo Add Board Observers KANSAS...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma
June 11, 2021 09:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical...
0c16d4f934b396fffd79.png
TripleBlind Receives Investment from Mayo Clinic, Expanding Current Collaboration
April 27, 2021 09:00 ET | TripleBlind
KANSAS CITY, Mo., April 27, 2021 (GLOBE NEWSWIRE) -- Today, TripleBlind announced that it expanded its collaboration with Mayo Clinic, which invested in a seed extension round, the only investor...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic
February 08, 2021 15:21 ET | Sorrento Therapeutics, Inc.
The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic Clinical studies utilizing the ADNAB™ platform are ongoing at the Mayo Clinic; and are evaluating multiple...
0c16d4f934b396fffd79.png
TripleBlind Collaborates with Mayo Clinic on Next Generation Algorithm Sharing and Training on Encrypted Data
December 15, 2020 09:00 ET | TripleBlind
KANSAS CITY, Mo., Dec. 15, 2020 (GLOBE NEWSWIRE) -- TripleBlind announced today it is collaborating with Mayo Clinic researchers who will use TripleBlind tools to validate interoperability of...
LOGO.jpg
Vivos Inc Completes Surrogate Lymph Node Testing Using Mouse Spleen Injections Demonstrating Uniform Perfusion and Stability
December 09, 2020 09:30 ET | Vivos Inc.
Richland WA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it worked with Mayo Clinic doctors to design and then conduct tests on the...